COPD Clinical Trial Tracker — Monitor the Chronic Obstructive Pulmonary Disease Pipeline

Why COPD trial monitoring is valuable in 2026

Chronic obstructive pulmonary disease (COPD) affects over 16 million diagnosed Americans and represents one of the largest unmet needs in respiratory medicine. Despite the commercial dominance of triple inhaled therapy (LAMA/LABA/ICS), the search for disease-modifying treatments — approaches that actually slow lung function decline rather than just manage symptoms — is driving an active and increasingly complex trial landscape.

Key competitive areas to monitor in the 2026 COPD pipeline:

• Type 2 inflammation biologics — dupilumab (IL-4Rα) approved for COPD in eosinophilic patients in 2024; multiple follow-on programs targeting IL-33, TSLP, and IL-13 entering COPD trials; competitive spillover from asthma biologics
• Non-type 2 / neutrophilic COPD — the majority of COPD patients are non-eosinophilic; IL-17, IL-8, CXCR2 programs targeting neutrophilic airway inflammation remain an active and unresolved competitive space
• Alpha-1 antitrypsin deficiency (AATD) — a genetically defined COPD subtype; augmentation therapy is approved; gene therapy and AAT mimetic approaches entering trials (Takeda, Inhibrx, others)
• Lung tissue repair / regeneration — PDE4B inhibitors, senolytic agents, and matrix metalloproteinase programs targeting emphysema reversal
• COPD exacerbation prevention — anti-infective approaches, RSV vaccines, and novel anti-inflammatory programs targeting the exacerbation cascade
• Lung microbiome interventions — early phase programs examining microbiome modulation for COPD stability

What we monitor for COPD

Our daily ClinicalTrials.gov pipeline can be configured for precise COPD trial tracking:

• Condition keywords: "COPD", "chronic obstructive pulmonary disease", "emphysema", "chronic bronchitis", "alpha-1 antitrypsin deficiency", "AATD"
• Mechanism keywords: "IL-33 COPD", "TSLP COPD", "PDE4 COPD", "CXCR2", "senolytic COPD", "lung regeneration" — track any specific mechanism
• Phase filter: Focus on Phase 2/3 for near-term commercial threats, or include Phase 1 for early competitive intelligence
• Sponsor filter: Industry-sponsored only (competitive commercial landscape) or all including academic
• Population subtype: Keywords like "eosinophilic", "non-eosinophilic", "frequent exacerbator", "GOLD 2-4" for subgroup-specific monitoring

The dupilumab approval and its competitive ripple effects

FDA approval of dupilumab for COPD in eosinophilic patients in 2024 marked the first new mechanism approved for COPD in decades and opened the floodgates for type 2 biologic trials in the condition. The competitive landscape that has emerged:

• Astegolimab (IL-33, Genentech/Roche) — completed Phase 3 in COPD; results define the competitive ceiling for IL-33 approaches
• Itepekimab (IL-33, Sanofi/Regeneron) — Phase 3 AERIFY program ongoing; direct IL-33 vs. IL-4Rα competitive question
• Tezepelumab (TSLP, AZ/Amgen) — approved in asthma; COPD program underway
• Multiple next-generation type 2 biologics entering Phase 2 COPD trials following dupilumab's success

BD teams and investors tracking the COPD biologic space need visibility into new trial registrations the moment they appear on ClinicalTrials.gov.

Who uses COPD trial monitoring

• Respiratory/pulmonary BD teams at pharma and biotech — tracking competitor programs across COPD subtypes and mechanisms
• Respiratory disease investors — monitoring pipeline milestones and competitive positioning
• Pulmonology-focused CROs — identifying enrollment competition for active COPD studies
• COPD patient advocacy organizations (COPD Foundation, Alpha-1 Foundation) — staying current on trial availability
• Pulmonologists and academic researchers — monitoring commercial pipeline for collaboration or IIT opportunities

Pricing

Basic — $49/month: 3 disease/keyword profiles, daily digest, ClinicalTrials.gov monitoring.

Professional — $149/month: Unlimited profiles, phase and sponsor filters, digest frequency options.

Team — $299/month: Everything in Professional for up to 5 users.

All plans include a 14-day free trial. Not charged until day 15.